RESEARCH virological failure (VL ≥1 000 copies/mL) on at least two occasions 2 months apart and were then switched to a PI-based regimen.
Setting
Records were reviewed for all ART patients from eight public health facilities in central Johannesburg (subdistrict F). The facilities were two hospitals, one community health centre (CHC) and five primary healthcare clinics.
Data collection
The total cohort of 825 represented all patients from the facilities who initiated their second-line treatment between 1 January 2014 and 31 December 2015. This cut-off period was chosen to give the cohort patients a minimum of 1 year to receive their annual standard-of-care VL test. In order to isolate this cohort, data were extracted from the TIER.Net database for all patients active on ART (N=56 894). A total of 53 287 patients on first-line treatment were then excluded, leaving a total of 3 607 active patients on second-line treatment. Of these second-line patients, 2 781 were excluded because they initiated their second-line treatment before 1 January 2014. Of the remaining 826 patients who met the inclusion criteria, one had missing information and was omitted, and the remaining 825 were followed until data collection ended in July 2017. The participant flow diagram is shown in Fig. 1 .
All data were exported from TIER.Net to Excel 2016 Professional Plus (Microsoft, USA), where data were cleaned and formatted. The following variables were extracted for further analysis: treatment facility, gender, date of birth, age at ART switch, ART start date, second-line treatment start date, baseline ART regimen, baseline CD4+ cell count at start of ART, most recent CD4+ cell count (after ART switch), most recent VL (after ART switch), and retention-in-care status.
CD4+ cell counts were presented in four ranges for values ≤500 cells/µL and as a single category for all values >500 cells/µL. Since this cohort started ART before 2017, the CD4+ cell count disaggregation reported here was guided by the WHO guidelines. [14] [15] [16] VL was categorised into suppressed or unsuppressed based on the WHO threshold for suppression of <1 000 copies/mL. [7, 17] Retention-in-care status was assessed as at 31 July 2017, and categorised into active in care (AIC), lost to follow-up (LTFU), transferred out (moved outside a facility included in the analysis), or known to be dead.
The datasets analysed during the study are available from the corresponding author (SBG) on reasonable request.
Data analysis
Data from the Excel spreadsheets were exported to Stata version 15.1 (StataCorp, USA) for analysis. Continuous data were summarised using medians (and interquartile ranges where appropriate) and then grouped into categories to define demographic characteristics. Three outcome variables, CD4+ cell count levels, VL and retention-in-care status, were quantified at the cohort level, then analysed further to identify associations between outcome variables and selected demographic characteristics with Pearson's χ 2 tests. Furthermore, multiple logistic regression models were built for the outcome variables to identify independent predictors. These predictors were reported as unadjusted and adjusted odds ratios (ORs), with 95% confidence intervals (CIs) and p-values; p<0.05 was considered significant. Survival analysis (for the LTFU category) was conducted using the Kaplan-Meier estimator to understand the pattern of attrition. 
Ethical considerations

Results
Demographic profile (Table 1)
At the start of first-line ART, the cohort had an average baseline CD4+ count of 109 cells/µL, and 59.9% of the patients were female. The median age at the start of second-line treatment was 37 years, the median duration of first-line ART was 63 months, and patients switched from first-line to second-line treatment after 38 months on average. Zidovudine/ lamivudine/lopinavir/ritonavir (AZT/3TC/ LPV/r) was the most common second-line antiretroviral, with 68.0% of the cohort on this combination. The other 32.0% were on tenofovir/lamivudine/lopinavir/ritonavir (TDF/3TC/LPV/r).
For the cohort, a single site (Hillbrow CHC) provided 352 (42.7%) of patients, while Charlotte Maxeke Johannesburg Academic Hospital, South Rand Hospital and Yeoville Clinic were the only other facilities that provided more than 100 patients. Just under half of the patients had been transferred to their current treatment facilities from outside subdistrict F, while the other 56.9% were new patients who had commenced treatment in subdistrict F.
Active ART patients
N=56 894
First-line treatment n=53 287
Missing information n=1
Second-line cohort with complete records n=825
Second-line treatment n=3 607
Initiated second-line treatment before 1 January 2014 n=2 781
Initiated second-line treatment between 1 January 2014 and 31 December 2015 n=826 
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Outcome variables
A summary of the cohort outcome variables is set out in Table 2 .
In order to evaluate predictors for the three outcome variables, CD4+ cell count, VL and retention-in-care status, correlations were explored with different demographic characteristics. Gender, new v. transferred-in patients, total duration of ART, second-line regimen, baseline CD4+ cell count at ART start and most recent VL were all correlated with the CD4+ cell count outcome. Age at ART switch, gender, new v. transferred-in patients (patients who were now on second-line treatment in subdistrict F, but started their initial treatment in a different region) and most recent CD4+ cell count were all correlated with VL outcomes, while facility, duration of ART, baseline CD4+ cell count at start of ART and most recent VL were all significantly correlated with retention-in-care status outcomes. The Pearson's χ 2 values are presented in Table 3 , and to ensure that there were no affirmative confounders, all variables underwent further logistical analysis with ORs and adjusted ORs.
One affirmative confounder was identified (age at ART switch and retention-in-care status) and added to the statistically significant correlations, which are presented in Table 4 .
CD4+ cell count
For the cohort, the most recent median CD4+ cell count was 286 cells/µL, which represented a 177 cells/µL (270%) increase from the 109 cells/µL baseline count at the start of ART. Of the patients, 132 (22.5%) achieved healthy CD4+ cell counts >500 cells/µL, whereas only 22 (3.1%) were above this threshold with their baseline CD4+ cell counts.
Males (OR 0.53, 95% CI 0.32 -0.88) and patients transferred in to their current ART facility (OR 0.54, 95% CI 0.33 -0.88) were both less likely to have a CD4+ cell count >500 cells/µL at last measurement than females and new patients, respectively. Patients taking AZT/3TC/ LPV/r as their regimen were also less likely (OR 0.42, 95% CI 0.26 -0.69) to have a CD4+ cell count >500 cells/µL than patients taking 
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TDF/3TC/LPV/r. Patients who had been on ART for at least 10 years were more likely to achieve CD4+ cell counts >500 cells/µL than patients who had been on ART for ≤4 years, with an OR of 3.23 (95% CI 1.51 -6.91).
Patients with virological failure on secondline treatment (OR 0.15, 95% CI 0.052 -0.42) were less likely to achieve CD4+ cell counts >500 cells/µL than virologically suppressed patients.
VL suppression
The average time (based on VL dates included in patient records) to VL measurement after ART switch was 20 months, and the most recent median VL was 124 copies/mL. A total of 570 patients (83.1%) achieved viral suppression based on the 1 000 copies/mL threshold. VL suppression was less likely in male patients than in females (OR 0.54, 95% CI 0.36 -0.81) and in patients transferred from ART facilities outside subdistrict F (OR 0.58, 95% CI 0.38 -0.89). Suppression was also directly related to age at ART switch, with the oldest group (patients aged ≥50 years) far more likely to achieve viral suppression than the youngest group (<25 years) (OR 5.01, 95% CI 1.59 -15.79).
Retention-in-care status
As a cohort, 597 patients (72.4%) remained AIC until data collection ended in July 2017. Of the outstanding patients, 161 (19.5%) were lost to follow-up, while 59 (7.2%) were transferred or moved out of subdistrict F, and 8 (1.0%) died. Total duration of ART was a significant predictor of retention-in-care status, as patients on ART for 5 -9 years (OR 0.47, 95% CI 0.32 -0.68) and >10 years (OR 0.54, 95% CI 0.30 -0.96) were approximately twice as likely to remain AIC for the duration of the study as those on ART for <5 years. Age at ART switch showed that patients aged >50 years (OR 0.36, p=0.053) were most likely to be retained in care.
Three facilities, Hillbrow CHC (OR 0.27, 95% CI 0.16 -0.44), Jeppe Clinic (OR 0.38, 95% CI 0.16 -0.88) and South Rand Hospital (OR 0.24, 95% CI 0.12 -0.47) were less likely than the others to have patients lost to follow-up. Patients with virological failure on second-line treatment were almost four times (OR 3.63, 95% CI 2.19 -6.02) more likely to be lost to follow-up than virologically suppressed patients. Patients with baseline CD4+ cell counts between 351 and 500 cells/µL at the start of ART were three times (OR 3.13, 95% CI 1.50 -6.56) more likely to be lost to follow-up than patients with a CD4+ cell count <101 cells/ µL. No other baseline CD4+ cell count categories or most recent CD4+ cell counts were significant predictors of retention-incare status.
Survival analysis (Fig. 2) shows an expected decrease in patient retention in care. However, the drop becomes steadier from month 100 (just over 8 years on treatment) and declines sharply at month 150 (12.5 years on treatment). 
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Discussion
Global intentions for successful scaling up of ART include ensuring that 90% of all patients receiving WHO-endorsed ART are retained in care with suppressed VLs. [18] Switching treatment-failing patients from first-line to second-line regimens has been policy in the SA public health setting since inception of the ART programme in 2004. [11] However, not much has been done to describe the longterm clinical outcomes of second-line cohorts, [19] particularly in this setting, highlighting the value of our findings. Patients starting second-line treatment tended to have low CD4+ cell counts, but 83.1% of our cohort showed viral suppression after switching from first-line treatment, demonstrating similar suppression rates to 
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historical first-line treatment (85% suppression rate) in Johannesburg subdistrict F. [20] The low CD4+ cell counts despite viral suppression could be indicative of slow CD4+ cell count recovery. [21] Just under three-quarters (72.4%) of our patients remained in care in the study sites over the reported period. The remaining 27.6% were no longer receiving care at the study sites (i.e. transferred out), were lost to follow-up or died. This is slightly lower than the reported retention rate of 78% in a first-line treatment cohort from inner-city Johannesburg. [22] Recent VL suppression and recent CD4+ cell counts >500 cells/ µL were both correlated with a number of independent variables: males and transferred-in patients both had lower CD4+ cell counts and greater virological failure. Patients on TDF/3TC/LPV/r and patients with long durations of ART were correlated with CD4+ cell counts >500 cells/µL, but they did not show any statistically significant relationships with VL suppression. Age at ART switch did, however, show a strong stepwise correlation with virological failure, with patients aged 25 -34 years, 35 -50 years and >50 years each increasingly more likely to achieve viral suppression than patients aged <25 years.
There was also a correlation between age at ART switch and retention-in-care status, as patients >50 years of age were more likely to remain AIC. This is in keeping with recent findings from Kenya that older ART patients were more likely to remain in care than younger patients, [23] and older pooled Kenyan, Tanzania, Mozambican and Rwandan data. [24] Only three facilities, Hillbrow CHC, Jeppe Clinic and South Rand Hospital, were strongly associated with raised AIC rates. These findings are consistent with various reports released between 2014 and 2018 that described these three facilities, together with a few others in the Johannesburg metropolitan municipality, as providing high standards of care, their patients having comparatively short waiting times and good clinical support services (within facilities and from external health systems-strengthening support partners) in terms of implementation of clinical guidelines and leadership. [25] [26] [27] Ensuring quality of care, a sufficient space to provide ART services and shorter waiting times for ART patients have long been associated with patient retention and adherence to treatment. [28, 29] Additionally, these findings demonstrate effective task shifting of ART services within the healthcare facilities and decentralisation of services between primary and higher levels of care (secondary and tertiary), [29] [30] [31] as well as out of the facility (e.g. Hillbrow CHC runs adherence clubs for stable, adherent ART patients). These three facilities could therefore be identified as providing models in terms of retention in care and adherence to treatment for other health facilities to follow.
Patients with baseline CD4+ cell counts at the start of ART of 351 -500 cells/µL were approximately three times more likely to be lost to follow-up than patients with CD4+ cell counts ≤100 cells/µL. It could be assumed that since patients with low CD4+ cell counts are at an increased risk of opportunistic infections and other HIVrelated complications, and of experiencing drug toxicity related to ART and HIV complications, they tend to remain in HIV care because they are ill and/or accessing care for multiple illnesses. [32] [33] [34] Patients who have been on ART for ≥5 years are ~50% less likely to be lost to follow-up than patients in their first 4 years of treatment. This evidence provides an opportunity for engaging patients from treatment initiation by providing additional support and counselling to ensure that they remain engaged throughout their treatment span. [35] Support and counselling benefits have been reported in firstline treatment cohorts where similar retention-in-care patterns were identified. [35, 36] Mberi et al. [36] described a group receiving care from 2002 to 2012 at a high-volume SA ART clinic. They reported 40% of the patients being LTFU within 12 months of starting ART, a slight subsequent decrease in retention, a sharp decline from year 5, and plateauing at year 8. Our group displayed better long-term retention, with the initial sharp decline only being seen at year 8 and plateauing halfway through year 12. Patient and programme monitoring, actively implementing adherence and retention programmes, betterquality service delivery (described above) and possible improved accountability on the part of patients may have resulted in these slightly enhanced retention rates. The implication is that aggressively enforcing adherence and retention strategies will lead to better clinical outcomes and higher retention-in-care rates.
Study limitations
The analysis was performed for a limited number of facilities in one SA district and may not necessarily be generalisable to all the other districts. Owing to inconsistencies in data quality from TIER.Net it was difficult to accurately calculate time to second-line treatment from the exact time of treatment failure, as well as the time to suppression data. A standard VL result of 124 copies/mL is captured RESEARCH into TIER.Net for patients who have a laboratory result reported as lower than detectable level (instead of actual values). This affects the calculated median and interquartile range values.
Conclusions
Our study described the long-term clinical outcomes of secondline patients and identified demographic, laboratory and clinical factors that predicted virological failure in this group. The patients in this cohort did well virologically after switching to second-line therapy, although poorer outcomes remain an issue, especially among younger and male patients. The study also identified transfer of patients and patients on AZT/3TC/LPV/r as subdemographics that were likely to be associated with poorer laboratory outcomes. All these are easily identifiable factors that may trigger added adherence and support interventions including intensive patient engagement during the first few years of ART, targeted population-specific adherence support programmes, using mobile health solutions for patient communication and appointment reminders, prioritising male and youth-friendly ART adherence and retention initiatives, and implementing a single patient identifier to accurately monitor patient and programme outcomes.
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